Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Zika Vaccines Market 2019: by Company Profile, Deals Type, Funding, Clinical Trials Insight

helps in immunization and prevention against the diseases caused by Zika virus. Aedes mosquitoes are the source of this virus that belongs to genus Flavivirus. Blood transfusion and sexual contact can...

CERS : 4.49 (+0.45%)
GSK : 42.60 (+0.16%)
IMV.TO : 3.75 (-3.85%)
INO : 2.32 (+3.11%)
NLNK : 1.49 (+8.76%)
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

GWPH : 121.48 (+2.85%)
QGEN : 28.11 (-1.33%)
ILMN : 313.83 (+1.42%)
INO : 2.32 (+3.11%)
Biotechs Endeavour to Increase Access to Cancer Treatments

Cancer is the second leading cause of death globally and was responsible for approximately 9.6 million deaths in 2018, according to the World Health Organization (WHO). Statistically, cancer is the cause...

ONPH : 0.0300 (-6.25%)
AGEN : 2.56 (-2.29%)
INO : 2.32 (+3.11%)
GERN : 1.48 (+3.50%)
ACST : 1.99 (-2.45%)
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes of Health (NIH) grant in support of...

INO : 2.32 (+3.11%)
Inovio (INO) Down 16.1% Since Last Earnings Report: Can It Rebound?

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INO : 2.32 (+3.11%)
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming investor conferences:

INO : 2.32 (+3.11%)
Inovio (INO) Down More Than 30% in 3 Months: Here's Why

Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.

AZN : 43.72 (-0.34%)
SNY : 45.94 (-0.50%)
REGN : 297.99 (-0.73%)
INO : 2.32 (+3.11%)
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100

Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.

SNY : 45.94 (-0.50%)
REGN : 297.99 (-0.73%)
INO : 2.32 (+3.11%)
ALXN : 100.73 (+2.36%)
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients...

INO : 2.32 (+3.11%)
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

AZN : 43.72 (-0.34%)
SNY : 45.94 (-0.50%)
INO : 2.32 (+3.11%)
QGEN : 28.11 (-1.33%)
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Lags Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of -7.14% and -97.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

INO : 2.32 (+3.11%)
Inovio: 2Q Earnings Snapshot

PLYMOUTH MEETING, Pa. (AP) _ Inovio Pharmaceuticals Inc. (INO) on Thursday reported a loss of $29.4 million in its second quarter.

INO : 2.32 (+3.11%)
Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of synthetic DNA technology targeted against cancers and infectious...

INO : 2.32 (+3.11%)
Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the closing of a private placement in the form of convertible bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately...

INO : 2.32 (+3.11%)
Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INO : 2.32 (+3.11%)
Inovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that second quarter 2019 financial results will be released after the market close on August 8, 2019. Following the release, the company will...

INO : 2.32 (+3.11%)
Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS) were published...

INO : 2.32 (+3.11%)
Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

AZN : 43.72 (-0.34%)
SNY : 45.94 (-0.50%)
INO : 2.32 (+3.11%)
REGN : 297.99 (-0.73%)
Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has sharpened its corporate strategy to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop...

INO : 2.32 (+3.11%)
Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals (NASDAQ: INO), announced today that the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting...

INO : 2.32 (+3.11%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.71 , AIZ +1.89 , SBAC +1.73 , SO +0.45 , WELL +0.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar